Drug Profile
Serotonin agonist-intranasal - Adhera Thearpeutics
Alternative Names: Intranasal serotonin agonist - Nastech; Intranasal triptan - Nastech; Triptan-intranasal - NastechLatest Information Update: 17 Apr 2019
Price :
$50
*
At a glance
- Originator Nastech Pharmaceutical Company
- Developer Marina Biotech
- Class Tryptamines
- Mechanism of Action Serotonin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Migraine
Most Recent Events
- 03 Feb 2017 Discontinued - Phase-I for Migraine in USA (Intranasal)
- 09 Jun 2004 Suspended - Phase-I for Migraine in USA (Intranasal)
- 07 May 2002 Phase-I clinical trials in Migraine in USA (Intranasal)